Join us in this interactive virtual meeting with financial advocacy experts to discuss tips for communicating and collaborating across teams, preparing for the new calendar year, and getting involved with the Financial Advocacy Network.

Testing for measurable residual disease can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia. Unfortunately, routine MRD testing is variable. This three-part webinar series is aimed at building capacity to implement, expand, and sustain MRD testing for patients with adult B-cell ALL at cancer programs and practices of all resource levels.

A series of sessions designed to strengthen your program’s operations, accelerate your knowledge in oncology business, and take on this rapidly changing healthcare landscape.

Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors. Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities.